Understanding how ME2 loss affects pancreatic cancer growth
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer
This study is looking at how a specific genetic change called ME2 loss affects the growth and spread of pancreatic cancer, with the goal of finding new treatment options that could help patients live longer and healthier lives.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10897233 on NIH RePORTER |
What this research studies
This research investigates the role of a specific genetic alteration, ME2 loss, in the development and progression of pancreatic cancer. By using advanced cell culture models, organoids, and mouse models, the team aims to uncover how ME2 deletion influences tumor growth and metastasis. The study seeks to identify new personalized treatment options that could improve survival rates for patients with pancreatic ductal adenocarcinoma. Through high-throughput screening, the researchers will explore the signaling pathways affected by ME2 loss, potentially leading to novel therapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with ME2 loss or related genetic alterations.
Not a fit: Patients with pancreatic cancer who do not have genetic alterations related to ME2 or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new personalized therapies that significantly improve survival for pancreatic cancer patients.
How similar studies have performed: Other research has shown promise in targeting genetic alterations in cancer, suggesting that this approach could lead to meaningful advancements in treatment.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Singh, Pankaj Kumar — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Singh, Pankaj Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.